NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

OPTIMISE-CKD Drug Utilization

CompletedN/A

Sponsor: AstraZeneca

Conditions: Chronic Kidney Disease

Countries: United States, Japan, Sweden

This is a multi-national, observational study program using secondary data sources to address research questions related to 1) real-world dapagliflozin utilisation in CKD and potential for further utilisation, 2), the current CKD treatment landscape and 3) real-world effectiveness of dapagliflozin in CKD (pending feasibility assessment).

Eligibility overview

Sex: ALL

Age: 18 Years to 130 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Adult patients (aged ≥18 years)
* Chronic kidney disease (diagnosis code, uACR \>30mg/g or 2 eGFR ≥90 days apart, second value ≥75ml/min/1.73m2)
* ≥365 days continuous enrolment in database

Exclusion Criteria:

* History of type 1 diabetes, gestational diabetes or dialysis
* History of dapagliflozin 10mg prescriptions before index date

Locations (5)

Minneota, Minnesota, United States
Kyoto, Kyoto, Japan
Tokyo, Japan
Uppsala, Sweden
Uppsala, Sweden